Navigation Links
Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that activation of SIRT1, a member of the sirtuin family of enzymes, was shown to protect against neurodegenerative diseases such as Alzheimer's Disease and Amyotrophic Lateral Sclerosis in animal models. These findings appear in an article published in Volume 26, Number 13 of The European Molecular Biology Organization Journal (EMBO), Kim et al., 2007 entitled "SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis" which is also available now in the advance online publication.

It is well established that a progressive loss of neurons with age underlies a variety of debilitating neurological disorders including Alzheimer's Disease and Amyotrophic Lateral Sclerosis (ALS), neurodegenerative diseases which have been associated with reduced mitochondrial function. Sirtuins are a recently discovered class of enzymes that appear to affect the aging process in mammals and increase the number and function of mitochondria.

According to the findings in this paper, resveratrol, a SIRT1 activator, reduced the loss of neuronal function in the brain (hippocampus) and prevented learning impairment in a well established animal model of Alzheimer's Disease. This response was associated with SIRT1 dependent deacetylation of PGC1a. Resveratrol also promoted neuronal survival in cell based models of Alzheimer's Disease and ALS.

The three senior authors of the EMBO article include Sirtris co-founder and co-chair of the Scientific Advisory Board (SAB), David A. Sinclair, Ph.D., Department of Pathology and Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Harvard Medical School, and Sirtris SAB members Li-Huei Tsai , Ph.D. Howard Hughes Medical Institute, Picower Institute for Learning and Memory, Massachusetts Institute of Technology and Pere Puigserver, Ph.D., Dana Farber Cancer Institute and Department of Cell Biology, Harvard Medical School.

"This work is significant because it shows that a SIRT1 activator can protect against neurodegeneration, highlighting the therapeutic potential of SIRT1 activators," said David Sinclair.

Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris Pharmaceuticals added "These new data support our belief in SIRT1 as a therapeutic target for neurodegenerative disease, which expands the potential of our pipeline of SIRT1 modulators designed to treat a number of diseases of aging such as metabolic and mitochondrial disorders, and now neurological disorders."

Online copies of the article can be obtained at: http://www.nature.com/emboj

About Sirtris Pharmaceuticals

Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company's headquarters are in Cambridge, Massachusetts.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Sirtris Pharmaceuticals, its product candidates, and those candidates' clinical potential. These forward-looking statements about future expectations, plans and prospects of Sirtris Pharmaceuticals involve significant risks, uncertainties and assumptions, including risks related to the lack of results that would provide a basis for predicting whether any of the Company's product candidates will be safe or effective, or receive regulatory approval, the Company's potential inability to initiate and complete preclinical studies and clinical trials for its product candidates, the fact that none of the Company's product candidates has received regulatory approvals, the potential inability of the Company to gain market acceptance of the Company's product candidates, and those other risks factors that can be found in the Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those Sirtris Pharmaceuticals contemplated by these forward-looking statements. Sirtris Pharmaceuticals does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

Contact

Investor Contact:
Sirtris Pharmaceuticals, Inc.
Michelle Dipp, 617-252-6920
or
Media Contact:
Pure Communications
Sheryl Seapy, 949-608-0841


'"/>




Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
8. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
9. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
10. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
11. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  The Baylor ... received an in-kind gift from ... VeinViewer® Vision vein finder for the nursing ... students as they learn how to start ... with traditional technique. ...
(Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk ... technology, today announced the launch of LexisNexis ... solution that helps improve and optimize the quality ... of performance using severity-adjusted scores. By measuring provider ... critical solution to deliver better outcomes, improve the ...
(Date:2/10/2016)... 10, 2016 Convergence scenarios are ... various technologies that results in diverse solutions ... opportunities create a cyclical system where technology ... the development of new technologies. ... technology convergences, which are constantly fostering new ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... Emergency rooms provide emergency care to stabilize critical health issues, ... with dental emergencies at risk of losing a tooth or their smiles. Dr. Marine ... Common dental emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ... Care Association™ (ALCA) to conduct a survey that takes a closer look at cases ... illustrates the prevalence and causes of TBI among the aging population, and identifies the ...
(Date:2/10/2016)... ... , ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on ... year ended December 31, 2015 on Monday, February 29, 2016 after the market closes. ... following the release at 4:30 PM ET. Investors interested in participating by phone are ...
(Date:2/10/2016)... ... 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves ... The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp explains ... is March 16, 2016. A free review copy is available to the media ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX Health & Science, ... stainless steel (PLS) columns combine the strength of traditional stainless steel with the ... biological samples while operating at ultra-high pressures of 20,000 psi. The higher operating ...
Breaking Medicine News(10 mins):